Skip to main content

Table 4 Base case cost effectiveness results (with 95% CIs)

From: The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Cohort Evaluated Teriparatide vs. No Treatment Teriparatide vs. Bisphosphonate
PMO Patients (100% Female), age 69 years, T-Score = −3.0
historical vertebral + incident vertebral fracture €5,897 / QALY €19,371 / QALY
  (€5,128 – €6,612) (€18,413 – €20,424)
incident vertebral fracture €18,701 / QALY €36,995 1 / QALY
  (€17,612 – €20,062) (€35,252 – €38,944)
GIOP Patients (80% Female), age 69 years, T-Score = −2.5
historical vertebral + incident vertebral fracture €3,271 / QALY €15,155 / QALY
  (€2,691 – €3,853) (€14,406 – €15,881)
incident vertebral fracture € 7,330/ QALY €20,826 / QALY
  (€6,650 – €8,062) (€19,831 – €21,854)